For its fourth fiscal quarter (ending December 31), Iovance Biotherapeutics Inc (NASDAQ: IOVA) has reported a -42% decline in E.P.S. from $-0.45 a year ago to $-0.26 in the current quarter. E.P.S. were $-1.28 for the latest four quarters through December 31 versus $-1.89 for the same period a year ago — a decline of -32%.
Recent Price Action
On 2/27/25, Iovance Biotherapeutics Inc (NASDAQ: IOVA) stock declined modestly by -1.7%, closing at $5.26. Moreover, this decline was accompanied by unusually high trading volume at 151% of normal. Relative to the market the stock has been weak over the last nine months and has declined -6.9% during the last week.
Current PriceTarget Research Rating
Iovance Biotherapeutics has a current Value Trend Rating of F (Lowest Rating). This rating combines consistent signals from two proprietary PTR measures of a stock’s attractiveness. Iovance Biotherapeutics has a poor Appreciation Score of 20 and a very low Power Rating of 8, and the Lowest Value Trend Rating results.
Rating Review
In light of this new information and negative market action we are reviewing our current Overall Rating of F. This review will be completed in the next several days.
Be the first to comment